Can a cancer drug turn back the clock on aging?

NCT ID NCT05835999

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether a low dose of everolimus, a drug used in cancer, can safely improve signs of aging in 106 adults aged 55-80 who have insulin resistance or prediabetes. Participants take the drug daily or weekly for 24 weeks, and researchers measure changes in metabolism, heart function, and cognition. A younger group is included for comparison but does not receive the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

everolimus

What this could lead to

If successful, this could point toward a drug that slows some aspects of aging and improves metabolic health in older adults.

What could go wrong

This is a small, early-phase trial. The drug may not work as hoped, and everolimus can cause side effects like mouth sores or infections.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INSULIN RESISTANCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Insulin Resistance prediabetes syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Wisconsin-Madison

    Madison, Wisconsin, 53705, United States